AU2012308414A1 - Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer - Google Patents

Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer Download PDF

Info

Publication number
AU2012308414A1
AU2012308414A1 AU2012308414A AU2012308414A AU2012308414A1 AU 2012308414 A1 AU2012308414 A1 AU 2012308414A1 AU 2012308414 A AU2012308414 A AU 2012308414A AU 2012308414 A AU2012308414 A AU 2012308414A AU 2012308414 A1 AU2012308414 A1 AU 2012308414A1
Authority
AU
Australia
Prior art keywords
amino
phenyl
compound
methoxy
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012308414A
Other languages
English (en)
Inventor
Arthur Decillis
Gary Thomas Emmons
Joanne LAGER
Rodrigo RUIZ SOTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Exelixis Inc
Original Assignee
Sanofi SA
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Exelixis Inc filed Critical Sanofi SA
Publication of AU2012308414A1 publication Critical patent/AU2012308414A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012308414A 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer Abandoned AU2012308414A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US61/534,836 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US61/543,529 2011-10-05
US201161562670P 2011-11-22 2011-11-22
US61/562,670 2011-11-22
PCT/US2012/055387 WO2013040337A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2012308414A1 true AU2012308414A1 (en) 2014-05-01

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012308414A Abandoned AU2012308414A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Country Status (10)

Country Link
EP (1) EP2755654A1 (enExample)
KR (1) KR20140077911A (enExample)
AU (1) AU2012308414A1 (enExample)
BR (1) BR112014005858A2 (enExample)
CA (1) CA2848724A1 (enExample)
IL (1) IL231448A0 (enExample)
IN (1) IN2014CN02671A (enExample)
TW (1) TW201325592A (enExample)
UY (1) UY34339A (enExample)
WO (1) WO2013040337A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1940839B1 (en) 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
RS53020B (sr) * 2007-04-11 2014-04-30 Exelixis Inc. Kombinovane terapije koje sadrže hinoksalin inhibitor pi3k-alfa za upotrebu u lečenju kancera
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
IN2014CN02671A (enExample) 2015-07-03
WO2013040337A1 (en) 2013-03-21
TW201325592A (zh) 2013-07-01
IL231448A0 (en) 2014-04-30
WO2013040337A9 (en) 2014-04-03
UY34339A (es) 2013-04-30
CA2848724A1 (en) 2013-03-21
BR112014005858A2 (pt) 2017-06-13
EP2755654A1 (en) 2014-07-23
KR20140077911A (ko) 2014-06-24

Similar Documents

Publication Publication Date Title
JP7289876B2 (ja) Ｒｓｋ阻害剤として有用なカルボキサミド誘導体
CN103384670B (zh) 取代的咪唑并[1,2-b]哒嗪
ES2802296T3 (es) Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
CA3124678A1 (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JP2021522275A (ja) サイクリン依存性キナーゼ阻害剤としての２−アミノ−ピリジンまたは２−アミノ−ピリミジン誘導体
ES2558780T3 (es) Imidazopiridazinas como inhibidores de la cinasa Akt
CN113683616A (zh) Kras g12c突变蛋白抑制剂
CN105461694B (zh) 取代的杂芳基化合物及其组合物和用途
JP2025536259A (ja) 三環式化合物及びその使用
ES2425068T3 (es) Compuestos de pirido[2,3-d]pirimidin-7-ona como inhibidores de PI3K-alfa para el tratamiento del cáncer
GB2465405A (en) Triazine, pyrimidine and pyridine analogues and their use in therapy
JP2006508981A (ja) 癌を治療するためのインドリノンと化学療法剤との組み合わせ投与
CN114728934B (zh) 杂环衍生物、药物组合物和它们治疗或改善癌症的用途
ES3037417T3 (en) Purine derivatives as sik-3 inhibitors
CN107531683A (zh) Usp7抑制剂化合物及使用方法
CN114716435A (zh) Kras g12c突变抑制剂
ES2930081T3 (es) Pirazolopirimidinas sustituidas útiles como inhibidores de quinasas
JP2022539208A (ja) チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
AU2013318672B2 (en) Means and method for treating solid tumours
TW201920141A (zh) Cdk4/6抑制劑及其用途
CN105050602B (zh) 作为pi3激酶抑制剂的吡啶化合物
WO2023078451A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
AU2012308414A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
WO2016153394A1 (ru) Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний
CN119745890A (zh) 吡咯烷[3,4-d]嘧啶衍生物在制备PARPs/ATR多靶点抑制中的应用

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period